Kelun-Biotech Presents Final Survival Analysis Results for Breast Cancer Drug Study
Kelun-Biotech said final overall survival analysis results from its Phase III OptiTROP-Breast01 study were presented at the 2026 ESMO Congress and published in Annals of Oncology.